Edition:
United Kingdom

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

167.27USD
24 Sep 2018
Change (% chg)

$2.29 (+1.39%)
Prev Close
$164.98
Open
$164.16
Day's High
$169.32
Day's Low
$162.18
Volume
51,175
Avg. Vol
104,785
52-wk High
$174.50
52-wk Low
$96.43

Select another date:

Tue, Jun 26 2018

Photo

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

RPT-UPDATE 4-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

GW Pharma wins U.S. approval for marijuana-derived epilepsy drug

June 25 An epilepsy treatment from GW Pharmaceuticals Plc on Monday secured an approval from the U.S. Food and Drug Administration, becoming the first cannabis-based drug to be approved in the country.

BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents

* GW PHARMACEUTICALS PLC REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

UPDATE 2-GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

* Cowen analysts expect $1.3 bln in sales by 2022 (Adds details, analyst comment, estimates, background)

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

BRIEF-GW Pharma Says Presenting CBD-OS Product In Advisory Committee Meeting With FDA On April 19

* GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 - SEC FILING Source text: (https://bit.ly/2HK1BW3) Further company coverage:

Select another date: